Clinical trials
Hormone Receptor Positive Breast Carcinoma clinical trials
Below are recruiting hormone receptor positive breast carcinoma clinical trials, each written for real people, not researchers. We’re tracking 126 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06224673RecruitingPhase 2
Testing ARX788 for HER2-low advanced breast cancer
This trial tests a new drug, ARX788, for people with HER2-low breast cancer that has spread or cannot be removed by surgery. The goal is to see if ARX788 helps shrink or control the cancer.
San Francisco, CaliforniaAges 18 years+ - NCT07020117RecruitingPhase 1
Study of AKY-1189 for advanced solid tumors
This trial tests a new radioactive drug, AKY-1189, for people with solid tumors that have spread or cannot be removed. It may help if other treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT06348134RecruitingPhase 2
Anti-HER2 Therapy Before and After Surgery for HER2-Positive Breast Cancer
This trial tests a targeted therapy (anti-HER2) given before and after surgery for Nigerian women with HER2-positive breast cancer. It aims to see if this treatment helps shrink tumors and improve outcomes.
Ikeja, LagosAges 18 years+ - NCT06361940RecruitingPhase 2
Short-term hormone therapy before breast cancer surgery
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
Milwaukee, WisconsinAges 18 years+ - NCT06388122Recruiting
Blood test study for HR+ breast cancer treatment monitoring
This study looks at a blood test (DiviTum TKa) to see how well it measures treatment response in people with hormone receptor-positive (HR+) breast cancer that has spread. The test may help doctors know if a treatment is working.
Jacksonville, FloridaAges 18 years+ - NCT06414733RecruitingPhase 1
HER-2 B Cell Peptide Vaccine for Advanced Cancers
This trial tests a vaccine that helps your immune system attack cancer cells that have HER2 or EGFR proteins. It is for people with advanced breast or gastrointestinal cancer whose disease has worsened after standard treatment.
Indianpolis, IndianaAges 18 years+ - NCT06439693RecruitingPhase 2
Sequential therapy for newly diagnosed HER2+ breast cancer that has spread
This trial tests a sequence of targeted therapies for people newly diagnosed with HER2-positive breast cancer that has spread to other parts of the body. The goal is to find a treatment plan that can potentially cure the cancer.
Boston, MassachusettsAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Little Rock, ArkansasAges 18 years+ - NCT06678269RecruitingPhase 1
Abemaciclib and radiation for metastatic breast cancer
This trial tests whether a targeted therapy (abemaciclib) combined with focused radiation (SBRT) to a bone tumor can help people with advanced breast cancer. It is for patients whose cancer is hormone receptor positive and HER2 negative, and who will continue abemaciclib after radiation.
Basking Ridge, New JerseyAges 18 years+ - NCT06691035RecruitingPhase 1
Targeting ESR1 mutation in hormone-positive breast cancer
This trial tests a new treatment for metastatic breast cancer that is hormone receptor-positive and HER2-negative, and has a specific genetic change called an ESR1 mutation. The goal is to see if targeting this mutation can help control the cancer.
Tampa, FloridaAges 18 years+ - NCT06756932RecruitingPhase 1
Bcl-2 inhibitor combo for advanced HR+ breast cancer
This trial tests a new Bcl-2 inhibitor (BGB-21447) combined with other therapies for advanced HR+/HER2- breast cancer that has already been treated with hormone therapy and a CDK4/6 inhibitor. It aims to see if these combinations are safe and effective.
Iowa City, IowaAges 18 years+ - NCT06805812Recruiting
Predicting outcomes of CDK4/6 inhibitors plus hormone therapy for advanced breast cancer
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
AvianoAges 18 years+ - NCT06961955RecruitingPhase 2
Shorter versus longer whole breast radiation for early-stage breast cancer
This trial compares a 5-day course of whole breast radiation plus a boost to the standard 9-day course for people with early-stage breast cancer who have certain risk factors, such as high-grade tumors or younger age. The goal is to see if the shorter treatment is just as safe and effective.
Salt Lake City, UtahAges 18 years+ - NCT07042581RecruitingPhase 4
Revaree Plus for vaginal dryness in breast cancer survivors
This trial tests a vaginal insert called Revaree Plus to see if it helps breast cancer survivors who have vaginal dryness or pain from hormone therapy. It may be a good option if you are on an aromatase inhibitor or tamoxifen and have discomfort.
Basking Ridge, New JerseyAges 18 years+ - NCT07044310RecruitingPhase 2
Probiotics for preventing bone loss during breast cancer hormone therapy
This trial tests if a probiotic supplement can help prevent bone loss in women with HR-positive breast cancer who are starting an aromatase inhibitor. You would take the probiotic daily and provide blood and stool samples to see how it affects your bone health.
Jacksonville, FloridaAges 18 years+ - NCT07195227RecruitingPhase 2
Camizestrant plus ribociclib for advanced breast cancer
This trial tests a combination of two drugs, camizestrant and ribociclib, for people with a certain type of advanced breast cancer (HR+/HER2-). It is for those whose cancer has grown or spread despite previous hormone therapy. The goal is to see if this new combination can help control the cancer.
DessauAges 18 years+ - NCT07214532Recruiting
Guiding CDK4/6 inhibitor use by a blood test in breast cancer
This trial is for women and men with early-stage, hormone-positive, HER2-negative breast cancer. It uses a blood test (Signatera) to detect tiny amounts of cancer DNA and only starts a CDK4/6 inhibitor (ribociclib or abemaciclib) if the test shows cancer DNA is present.
Birmingham, AlabamaAges 18 years+ - NCT07222215RecruitingPhase 2
Capacitabine with or without elacestrant for ER+ breast cancer
This trial tests if adding a new oral targeted therapy (elacestrant) to standard chemotherapy (capecitabine) works better than chemotherapy alone for people with a specific type of advanced breast cancer that is hormone-sensitive (ER-positive) and has stopped responding to hormone therapy.
Boston, MassachusettsAges 18 years+ - NCT06062498RecruitingPhase 2
Elacestrant alone or with a CDK4/6 inhibitor for advanced breast cancer
This trial compares a new hormone therapy (elacestrant) to the same therapy combined with a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib) for people with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has a mutation in the ESR1 gene. It aims to see if the combination works better than the single drug.
Chicago, IllinoisAges 18 years+ - NCT07341503Recruiting
Sleep after breast cancer study
This study looks at how sleep changes during breast cancer treatment and how those changes relate to certain markers in the body. It aims to help improve sleep and overall health for people with hormone receptor positive breast cancer.
Columbus, OhioAges 18 years+ - NCT07400523RecruitingPhase 3
Ribociclib for breast cancer with leftover disease after chemo
This trial tests ribociclib, a targeted therapy, for women with hormone receptor-positive, HER2-negative breast cancer who still have cancer cells in the breast or lymph nodes after initial chemotherapy. It aims to reduce the chance of cancer coming back.
Zhanjiang, GuangdongAges 18 years+ - NCT07454642RecruitingPhase 1
AVA6103 for advanced FAP-positive solid tumors
This trial tests a new drug called AVA6103 for certain advanced cancers that show a protein called FAP. It is for people who have already tried other treatments or cannot take them, and aims to see if the drug is safe and helps shrink tumors.
Grand Rapids, MichiganAges 18 years+ - NCT07484087Recruiting
Ablation vs. Surgery for Early Breast Cancer
This trial compares a less invasive treatment called ablation (which uses extreme cold to destroy the tumor) with standard surgery for early-stage breast cancer. It is for women aged 50 or older with a small, low-risk tumor that has not spread.
Beijing, Beijing MunicipalityAges 50 years+ - NCT07539038Recruiting
Exercise Program for Early-Stage Hormone-Positive Breast Cancer
This study tests whether a structured exercise program helps women with early-stage hormone-positive breast cancer who are taking endocrine therapy (hormone-blocking medications). The goal is to see if physical activity improves outcomes and quality of life during treatment.
Aviano, PordenoneAges 18 years+
Hear when a new Hormone Receptor Positive Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hormone receptor positive breast carcinoma?
- Yes. Clin2 currently lists 126 recruiting hormone receptor positive breast carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hormone receptor positive breast carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hormone receptor positive breast carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Hormone Receptor-Positive Breast Carcinoma
- Hormone-receptor-positive Breast Cancer
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Estrogen Receptor-Positive Breast Carcinoma
- Hormone Receptor Negative Breast Carcinoma
- Hormone Receptor Positive / HER2-negative Breast Cancer
- Hormone Receptor Positive Malignant Neoplasm of Breast
- Estrogen-receptor-positive Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.